Phaseline

Companies › Inhibikase Therapeutics

Inhibikase Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IKT-001
TIE2 receptor agonist
–Phase 3Pulmonary Arterial HypertensionJun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07365332IKT-001Phase 3Pulmonary Arterial HypertensionCardiovascularJun 2029

From the company's SEC filings

Cash and short-term investments of $159m on 2026-06-30; operating cash outflow about $50m a year; runway about 38 months at that burn, to Sep 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Theravance Biopharma Boston Scientific Braveheart Bio CeleCor Therapeutics MedTrace Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.